View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
March 9, 2022

Pionyr doses first subject in Phase Ib trial of PY314 for solid tumours

The Phase Ib trial will analyse PY314’s anti-tumour activity, safety, tolerability and pharmacokinetics.

Pionyr Immunotherapeutics has dosed the first subject in the Phase Ib expansion trial of its monoclonal antibody PY314 to treat solid tumour patients.

PY314 attaches to Triggering Receptor Expressed on Myeloid Cells 2 (TREM2) on the immunosuppressive, pro-tumour myeloid cell surface.

It can potentially reduce TREM2-expressing tumour-associated macrophages (TAMs), offering productive anti-tumour immunity. 

The Phase Ib expansion trial will analyse PY314 as monotherapy and along with pembrolizumab to treat predefined tumour types, including breast, ovarian, colorectal, lung and renal cancers.

The first subject who was dosed in the trial received PY314 as a monotherapy for advanced ovarian cancer while the combination arms of the trial commenced enrolment.

In this trial, anti-tumour activity, safety, tolerability and pharmacokinetics of PY314 will be analysed.

Furthermore, additional exploratory biomarkers, including the assessment of TREM2-expressing macrophages in tumour biopsy samples, will be evaluated.

The Phase Ib trial comes after the Phase Ia dose-escalation study that analysed the safety and tolerability of PY314 as monotherapy and with pembrolizumab for various solid tumours.

The multicentre Phase 1a trial in the US concluded subject enrolment and determined the recommended dose for the Phase Ib trial.

Pionyr Immunotherapeutics executive vice-president and chief medical officer Leonard Reyno said: “Dosing the first patient in our Phase Ib expansion study is an important milestone for the clinical development of PY314, having passed the first safety analysis and identifying a recommended dose for further evaluation.

“PY314 represents an opportunity to expand immunotherapy options for patients with advanced solid tumours, which continues to represent a major unmet need, especially among patients with checkpoint resistant tumours.”

The company signed a transformational collaboration in July 2020 through which Gilead Sciences obtained its minority interest.

Related Companies

Free Whitepaper

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy